Biotech & Pharma

Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform

28 sec read3 views0 listens

The HiBiT Target Cell Killing platform provides a bioluminescent system for precisely measuring direct and bystander cytotoxicity in antibody-drug conjugate development. This streamlined workflow allows biotech developers to distinguish between specific target cell death and neighboring antigen-negative cell killing in complex co-cultures without manual staining or washing. Professionals can now more accurately characterize linker-payload chemistry to optimize therapeutic coverage while minimizing damage to healthy tissue.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

Revolution Medicines presented positive clinical trial data for daraxonrasib, a pancreatic cancer treatment, showing a significant survival benefit over standard chemotherapy. This development highlights the potential of targeted therapies in oncolog...

Ali Nemati

Biotech & Pharma10 hours ago30 sec read

Illuminating the Drug Development Path with Cell-Based Reporter Assays

Cell-based reporter assays are transforming biologics development by providing sensitive, quantitative measurements of pathway activation in intact cells across discovery and clinical validation. For developers and tech professionals, these luciferas...

Ali Nemati

Biotech & Pharma10 hours ago31 sec read

Corning Advances the Organoid Revolution

Corning Life Sciences is scaling the adoption of organoids by providing specialized reagents and automated protocols that address critical barriers in standardization and reproducibility. These advancements allow biotech developers to leverage human-...

Ali Nemati

Biotech & Pharma10 hours ago30 sec read

Soon...the First Organ-on-a-Chip Qualified Drug Development Tool

The Emulate Liver-Chip S1 is nearing final FDA qualification as the first organ-on-a-chip drug development tool for predicting drug-induced liver injury. This advancement enables tech professionals to integrate high-throughput microfluidic systems an...

Ali Nemati

Biotech & Pharma10 hours ago29 sec read

Spatial Atlasing: Why Sensitivity Is the Real Frontier

The MERSCOPE Ultra platform and MERFISH 2.0 chemistry now enable high-sensitivity spatial transcriptomics that capture low-abundance transcripts and rare cell populations previously missed by lower-resolution tools. This shift from throughput to sens...

Ali Nemati

Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform

Related Articles

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

Illuminating the Drug Development Path with Cell-Based Reporter Assays

Corning Advances the Organoid Revolution

Soon...the First Organ-on-a-Chip Qualified Drug Development Tool

Spatial Atlasing: Why Sensitivity Is the Real Frontier